Atopic dermatitis (AD)
Conditions
Interventions
Case series:None
Sponsors
The First Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients aged = 18 years; Confirmed diagnosis of AD; Patients who are abrocitinib-naïve or have discontinued previous abrocitinib treatment for more than 30 days, and will receive abrocitinib as part of routine clinical practice during subsequent treatment; Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
Exclusion criteria
Exclusion criteria: Any condition that, in the opinion of the investigators, may interfere with patient’s ability to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Describe the baseline demographic and clinical characteristics of atopic dermatitis patients receiving treatment with abrocitinib tablets in the real world of China, as well as the changes during follow-up, including the clinical characteristics of atopic dermatitis, seasonal episodes and relapses, concomitant treatment patterns, other hypersensitive diseases, secondary infectious diseases, and comorbidities of other chronic diseases.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Describe the medication pattern and changes during follow-up of abrocitinib tablets;Describe the changes in clinical outcomes of patients evaluated by doctors during the follow-up period from baseline at weeks 2, 4, 12, 24, 52, and 64; ;Describe the changes in patient reported outcomes compared to baseline at weeks 2, 4, 12, 24, 52, and 64 during the follow-up period, as assessed by the patient themselves; ;Evaluate the changes in quality of life compared to baseline in patients receiving treatment with abrocitinib tablets at weeks 2, 4, 12, 24, 52, and 64; ;Evaluate the changes in satisfaction of patients and doctors receiving treatment with abrocitinib tablets at weeks 2, 4, 12, 24, 52, and 64 compared to baseline; ;Describe the treatment history of patients with atopic dermatitis in the year prior to receiving the current treatment with abuxitinib tablets and the treatment mode of atopic dermatitis during the study period. For patients who discontinued abrocitinib tablets during follow-up, describe the treatment mode after discontinuation until the end of follow-up; ;Describe the recurrence management model of patients with atopic dermatitis during the year prior to and follow-up to receiving this treatment with abrocitinib tablets; ;Describe the diagnostic mode of patients with atopic dermatitis before receiving this treatment with abrocitinib tablets;;Describe the diagnostic model of atopic dermatitis in patients with other allergic diseases, secondary infections, and/or comorbidities/histories of other chronic diseases prior to receiving treatment with abrocitinib tablets; ;Assess the changes in disease burden associated with atopic dermatitis (measured as direct medical expenses, direct non medical expenses, and indirect expenses) in patients during the year prior to and follow-up period of receiving this treatment with abrocitinib tablets.; | — |
Countries
China
Contacts
Public Contactgao xinghua
The First Hospital of China Medical University
Outcome results
None listed